Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070 by O'Boyle, Graeme et al.
O'Boyle,  Graeme,  Swidenbank,  I,  Marshall,  H,  Barker,  CE,  Armstrong,  Jane, 
White, SA, Fricker, SP, Plummer, R, Wright, M and Lovat, PE (2013) Inhibition 
of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070. British Journal of 
Cancer, 108. pp. 1634-1640. ISSN 0007-0920 
Downloaded from: http://sure.sunderland.ac.uk/7416/
Usage guidelines
Please  refer  to  the  usage guidelines  at  http://sure.sunderland.ac.uk/policies.html  or  alternatively 
contact sure@sunderland.ac.uk.
Inhibition of CXCR4–CXCL12 chemotaxis in
melanoma by AMD11070
G O’Boyle1, I Swidenbank1,5, H Marshall1, CE Barker1, J Armstrong2, S A White1, S P Fricker3, R Plummer4,6,
M Wright1,6 and PE Lovat*,1,6
1Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne NE2 4HH, UK; 2University of Sunderland, Sunderland,
UK; 3Genzyme Corporation, Framingham, MA 01701, USA and 4Northern Institute for Cancer Research, Newcastle University,
Newcastle upon Tyne NE2 4HH, UK
Background: Despite intensive research and novel adjuvant therapies, there is currently no cure for metastatic melanoma. The
chemokine receptor CXCR4 controls metastasis to sites such as the liver; however, the therapeutic blockade with the existing
agents has proven difficult.
Methods: AMD11070, a novel orally bioavailable inhibitor of CXCR4, was tested for its ability to inhibit the migration of melanoma
cells compared with the commonly described antagonist AMD3100.
Results: AMD11070 abrogated melanoma cell migration and was significantly more effective than AMD3100. Importantly for the
clinical context, the expression of B-RAF-V600E did not the affect the sensitivity of AMD11070.
Conclusion: Liver-resident myofibroblasts excrete CXCL12, which is able to promote the migration of CXCR4-expressing tumour
cells from the blood into the liver. Blockade of this axis by AMD11070 thus represents a novel therapeutic strategy for both B-RAF
wild-type and mutated melanomas.
Cutaneous melanoma represents an increasing world health
problem. In the United Kingdom alone, melanoma incidence has
quadrupled over the past 30 years, making it now the eighth most
common malignancy, resulting in more than 2000 deaths a year
from malignant disease (Cancer Research UK). Alarmingly,
melanoma is now the second most common cancer in the 15–34
years age group, emphasising the critical importance of early
intervention to prevent premature loss of life.
While the prognosis for early-stage disease is favourable,
being largely treatable through surgical excision alone and resulting
in 5-year survival rates of 495%, the outlook for patients
with advanced-stage disease, however, is extremely poor. Despite
intensive research, there is currently still no cure for metastatic
disease, which commonly targets the liver and results in 5-year
survival rates of o12% (Thompson, 2012), thus emphasising
the acute need for novel treatment strategies and targeted
therapies.
Study of genetic factors predisposing to melanoma has led to the
discovery of oncogenic mutations in NRAS and B-RAF (Davies,
2002; Dong et al, 2003; de Snoo and Hayward, 2005), which result
in constitutive activation of RAF-extracellular signal-regulated
kinase (ERK)/mitogen-activated protein kinase signalling and
the promotion of melanoma proliferation and chemoresistance
(Gray-Schopfer et al, 2007; Balmanno and Cook, 2009). Although
mutated B-RAF has been validated in recent clinical studies as a
therapeutic target for melanoma (Smalley, 2010), not all patients
harbour activating B-RAF mutations or respond to B-RAF
inhibitors, and the emergence of acquired resistance is already
recognised as a significant problem in the treatment of B-RAF-
V600E-mutated disease (Chapman, 2011). An acute demand for
alternative personalised approaches for more effective treatment
stratification hence remains.
Recently, substantial evidence has shown that chemokines and
chemokine receptors, which were first shown to induce directional
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migration of leukocytes from the blood into organs, may also be
involved in cancer metastasis. Chemokines are a family of small
chemoattractant cytokine-like proteins (8–11 kDa) that bind to and
activate G-protein-coupled seven-transmembrane domain (GPCRs
7TM) receptors. At present, approximately 50 chemokines and at
least 20 corresponding receptors have been identified. Classifica-
tion of the chemokines and their receptors is based on the position
and the number of conserved cysteine residues present, and to
date, four families have been identified: CXC, CX3C, CC and C. It
has been shown that they play an important role in tumour
development in a manner similar to leukocyte trafficking by
guiding the directional migration of cancer cells towards a gradient
of chemotactic cytokines secreted by organs such as the liver. These
observations suggest that targeting chemokine receptors may
provide a novel therapeutic strategy for preventing metastasis in a
wide range of cancers including melanoma.
The most common chemokine receptor known to be expressed
by cancer cells is CXCR4. Previous studies have also demonstrated
increased expression of CXCR4 in uveal melanoma tumours,
which correlated with disease progression (Franco et al, 2010).
However, in primary cutaneous melanoma, recent studies suggest
that there is a significant correlation between overexpression of
CXCR4 and survival or prognosis (Kuhnelt-Leddihn et al, 2012),
although this study did not examine differences between primary
and metastatic lesions.
The constitutive expression of the CXCR4 ligand, CXCL12, in
tissues such as the liver is thought to have a pivotal role in the organ-
specific dissemination of metastatic disease. It is widely accepted that
the expression of chemokine receptors by cancer cells leads to
migration, enhanced proliferation and cell survival by a mechanism
that includes CXCL12-mediated MAPK signalling (Balmanno and
Cook, 2009; Teicher and Fricker, 2010). The CXCR4–CXL12 axis
therefore represents an attractive therapeutic target for melanoma
(Teicher and Fricker, 2010). However, clinical translation has proven
difficult because of poor pharmacological profile of AMD3100, a
commonly described antagonist. AMD11070 has recently been
described as a novel orally bioavailable inhibitor of CXCR4 with a
more favourable pharmacokinetic profile (Mosi et al, 2012);
therefore; the aim of this study was to define its potential to inhibit
CXCR4–CXCL12-mediated chemotaxis in melanoma.
MATERIALS AND METHODS
Cell culture and reagents. CHL-1 (B-RAF-wild type (WT)) and
A375 (B-RAF-V600E mutated) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) with 10% (w v 1) fetal calf
serum and 1% glutamine. Cells were maintained at 37 1C in a
humidified 5% CO2 atmosphere. AMD11070 and AMD3100
(supplied by Genzyme Corporation, Framingham, MA, USA) were
freshly prepared at 1mgml 1 in citric acid/normal saline solution
and diluted to given concentrations in DMEM. Concentrations of
6.6mM AMD11070 or 2 mM AMD3100 were typically incorporated
in functional assays representing the maximum possible clinically
achievable concentrations in vivo allowing comparison of both
inhibitors (Stone et al, 2007). Human T cells were isolated and
activated as described previously (Newton et al, 2009). CXCL12-
neutralising antibody (R&D Systems, Abingdon, UK; Clone 79014)
was used at 100 mgml 1.
Immunofluorescence confocal microscopy. Archival human
liver tissue from patients with metastatic melanoma was obtained
with full ethical approval (Newcastle and North Tyneside
Research Ethics Service ref.: 08/H0906/95). Formalin-fixed
paraffin-embedded (FFPE) tissue sections were processed for
immunofluorescene based on previously described methodology
(Hong et al, 2009).
Specifically, FFPE sections were dewaxed in xylene for 10min
and rehydrated through 100, 95 and 70% ethanol to running water
and washed in TBS (pH 7.6; Tris-buffered saline). Antigen retrieval
was then carried out by pressure cooking slides in 10mM Tris
buffer (pH 7.4) for 1min, followed by rapid cooling in running
water and washing in TBS. Sections were then blocked with 20%
normal swine serum for 1 h before incubating with mouse anti-
CXCR4 antibody (10 mg/ml 1, overnight at 4 1C; R&D Systems;
MAB172) or mouse monoclonal antibody to a-smooth muscle
actin (a-SMA; Sigma-Aldrich, Dorset, UK). Sections were then
washed three times in TBS (as between all steps) and incubated
with FITC-conjugated goat-anti-mouse IgG (1/100, 1 h; Sigma).
Mouse on mouse reagent (Vector Laboratories, Peterborough, UK)
was then used to block mouse IgG as per the manufacturer’s
instructions and sections were blocked again with 20% normal
swine serum for 30min. Sections were then incubated with the
second primary antibody, mouse-anti-MelanA (1/500;1 h, RT;
Abcam, Cambridge, UK) and then TRITC-conjugated goat-anti-
mouse IgG (1/100, 1 h; Sigma). Sections were then counterstained
with DAPI for 15min and autofluorescence blocked using Sudan
Black (0.3% (w v 1) in 100% ethanol; 30min). Finally, sections
were mounted using fluorescence mounting medium (Dako,
Stockport, UK).
Myofibroblasts (passage 3) from histologically normal resected
liver tissue with informed donor consent and ethical approval from
the Newcastle and North Tyneside Research Ethics Committee
were cultured as described previously (Haughton et al, 2006).
Quiescent cells were cultured on plastic in media containing serum,
which then transdifferentiated into a myofibroblast phenotype.
Following permeabilisation with methanol and fixation with 2%
formaldehyde/0.2% glutaraldehyde in PBS, pH 7.4, fixed cells were
incubated in the presence or absence of a primary mouse
monoclonal antibody to a-SMA (Sigma; 1 : 1000) and detected
with a secondary anti-mouse IgG (whole molecule) fluorescein
antibody (green) or with an anti-human/mouse CXCL12/SDF-1
mouse monoclonal antibody (R&D Systems; 1 : 1000) detected with
a secondary anti-mouse IgG (whole molecule) rhodamine
(Sigma; 1 : 400) antibody (red). Mouse IgG1 isotype primary
antibody (Dako; 1 : 1000) was used a control. Cells were counter-
stained with DAPI and images were captured by confocal
microscopy (original magnification,  20).
Flow cytometry. Analysis of CXCR4 expression was performed as
described previously (Mellor et al, 2007) using anti-CXCR4 FITC
(MAB172; R&D Systems). Data were generated using a BD Canto
II (Oxford, UK) and analysed using the FlowJo software (Ashland,
OR, USA).
Cell viability. The commercial Cell Titer 96 Aqueous Non-
Radioactive Cell Proliferation Assay (MTS) was used to determine
cell viability following 24-h incubation with 6.6 mM AMD11070
according to the manufacturer’s instructions (Promega, South-
ampton, UK).
Chemotaxis. Migration assays were carried out as described
previously (Mellor et al, 2007) using an 8-mm transwell filter
(BD, Franklin Lakes, NJ, USA). A total of 200 000 cells were placed
in the upper chamber in a volume of 500 ml with the lower
chamber containing 800 ml serum-free media supplemented with
chemokine. The assay was incubated for 16 h at 37 1C before the
removal of excess cells and medium from both chambers. The
upper surface of the filter was gently swabbed before fixation in
100% ice-cold methanol for 1 h. Each filter was then stained using
haematoxylin before dehydration and mounting. Assays were
performed in triplicate, with the migrant cells in nine high-power
fields per filter being counted blindly. T cells’ isolation and
migration were performed as described previously (O’Boyle et al,
2012).
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Western blotting and transfection. Expression vectors for B-RAF-
WT and B-RAF-V600E (provided by R Marais, Patterson Institute
of Cancer Research, Manchester, UK), or pcDNA4 (Invitrogen,
Carlsbad, CA, USA) were transiently transfected using Lipofecta-
mine 2000 according to the manufacturer’s instructions. Preparation
of whole-cell lysates and western blotting for B-RAF (F-7; Santa
Cruz Biotechnology, Santa Cruz, CA, USA; diluted 1 : 1000), ERK1/
2, phosphorylated (Thr202/Tyr204) ERK1/2 (Cell Signalling Tech-
nology, Danvers, MA, USA; diluted 1 : 2000) and b-actin (Sigma;
diluted 1 : 40 000) were performed as described previously (Lovat
et al, 2008).
Statistical analyses. All results are expressed as mean values±
s.e.m. of replicate samples. The significance of changes was
assessed by the application of an ANOVA with Bonferroni post-
test. All data were analysed using the Prism 5 software (GraphPad,
San Diego, CA, USA).
RESULTS
A series of experiments were performed to demonstrate the
rationale underlying this study. A clear physical association
between metastatic melanoma tumour cells and liver-resident
myofibroblasts was observed in liver biopsy sections from patients
with metastatic melanoma (Figure 1A). Strong expression of
CXCL12 ligand was observed in primary myofibroblasts
(Figure 1B). Costaining of five patients indicated that the
metastatic melanoma cells in the liver of these patients express
the CXCL12 receptor, CXCR4 (Figure 1C).
Flow cytometry was used to measure the expression of CXCR4
on two commonly used melanoma cell lines (Figure 2A). Both
CHL-1 and A375 cells express comparable amounts of the CXCL12
receptor. These cells were migrated in a dose–response assay
towards CXCL12, with 10 nM inducing optimum migration of both
cell lines (Figure 2B).
As our study intended to address the effect of the CXCR4
inhibitor AMD11070 on cell migration, it was next necessary to
determine if the antagonist inhibitors had a detrimental effect on
cell viability. No significant difference in cell viability was observed
following culture of A375 or CHL-1 melanoma cells in the
presence of increasing concentrations of AMD11070 (Figure 3).
The specificity of the inhibitor was then demonstrated using
activated T cells. These cells express both CXCR3 and CXCR4
(O’Boyle et al, 2012). AMD11070 had no effect on migration
towards the CXCR3 ligand CXCL11, but did inhibit the response to
CXCL12 (Figure 4).
AMD3100 and AMD11070 were contrasted for their inhibition
of melanoma cell migration. Both inhibitors significantly blocked
chemotaxis of CHL-1 cells towards CXCL12 (Figure 5A). In
contrast, AMD11070 was more effective at inhibiting migration of
A375 than AMD3100 (78% and 21% inhibition, respectively,
Po0.05). Intriguingly, A375 cells harbouring the B-RAF-V600E
mutation displayed higher background migration in the absence of
chemokine. A scratch assay was used to assess the effect of the
CXCR4 inhibitors (Figure 5B). Cells treated with AMD11070 had a
significantly increased void size at all time points assessed
(Po0.05; Figure 5C).
We next considered the role of B-RAF in melanoma migration
towards CXCR4 and sensitivity to the inhibitor AMD11070.
Western blotting analysis indicated that both A375 and CHL-1
cells express similar levels of B-RAF overall (Figure 6A), so the
increased chemotaxis of A375 cells was not solely due to an
overexpression of B-RAF. We subsequently transfected CHL-1 cells
with vectors encoding WT and V600E B-RAF (Figure 6B). As
expected, this increased the amount of ERK activation in these
cells. A migration assay was then performed contrasting mock-
transfected with CHL-1 cells overexpressing WT and V600E
(Figure 6C). Intriguingly, overexpression of V600E but not WT
B-RAF increased the background migration of CHL-1 (Po0.05).
Importantly for the therapy of metastatic melanoma, however,
overexpression of either form of B-RAF did not affect the capacity
of AMD11070 to inhibit migration (Po0.01).
To reflect the recruitment to the liver in vivo, conditioned media
were collected from activated primary myofibroblasts. An ELISA
was performed to measure CXCL12; media conditioned for 72 h
contained 87±13 ngml 1 CXCL12. This media were then used as
the stimulus in a chemotaxis assay (Figure 7). As the conditioned
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Figure 1. The CXCR4/CXCL12 axis in melanoma migration to the liver. (A) Representative example of immunofluorescence staining of human liver
tissue from a patient with melanoma metastasis stained for a-SMA (green) and MelanA (red). Original magnification,  20; scale bar¼ 42mM. Image
is representative of five patients. (B) Representative example of immunofluorescence staining of primary myofibroblasts (passage 3). Cells were
incubated (i) without primary antibody or (ii) with antibody to a-SMA (green) or (iii) with anti-CXCL12 (red). (iv) Overlay of each image with
yellow staining indicating costaining of a-SMA and CXCL12. Cells were counterstained with DAPI (4’,6-diamidino-2-phenylindole) to visualise the
nuclei and images were taken by confocal microscopy (original magnification, 20; scale bar¼150mM). Image is representative of three
patients. (C) Representative example of double immunofluorescence staining of metastatic melanoma sections demonstrating staining with
(i) antibody to CXCR4 (green) or (ii) anti-MelanA (red). (iii) Overlay of each image with yellow staining indicating costaining of MelanA and CXCR4.
(iv) Cytofluorogram scatterplot of CXCR4 and MelanA staining. Cells were counterstained with DAPI to visualise the nuclei and images were taken
by confocal microscopy (original magnification,  20; scale bar¼ 150mM). Image is representative of five patients.
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media may contain several chemotactic factors, an important
control experiment was performed using a CXCL12-neutralising
antibody to indicate that the importance of the CXCL12–CXCR4
axis; the migration of melanoma cell lines was blocked by CXCL12
neutralisation. The migration response of CHL-1 cells was
significantly inhibited by both AMD3100 and AMD11070
(Po0.05); however, only AMD11070 inhibited migration of
A375 in this assay (Po0.05).
DISCUSSION
Chemokine receptors are cell surface G-protein-coupled receptors
and therefore amenable to inhibition by small-molecule antagonists.
AMD3100 (known as Plerixafor and Mozobil) is a CXCR4 antagonist
approved for use to mobilise haematopoietic stem cells to the
peripheral blood for collection and subsequent autologous trans-
plantation in patients with non-Hodgkin’s lymphoma and multiple
myeloma (Calandra et al, 2010). AMD3100 also has demonstrable
efficacy in murine models of metastasis (Yasumoto et al, 2006)
serving as proof-of-concept for targeting this axis in the management
of melanoma. However, the pharmacokinetics of AMD3100 are
unsuitable for use in human trials for melanoma therapy. To achieve
a therapeutically effective chemokine receptor blockade that limits
pathological cell migration, around 90% receptor occupancy must be
achieved with an antagonist (Schall and Proudfoot, 2011).
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Figure 3. AMD11070 has no affect on melanoma viability. Cell viability assay following 24 h treatment of CHL-1 (white bars) and A375 (black bars)
with AMD11070. Cell viability was calculated as a percentage relative to vehicle cells. Data represent mean values of three independent
experiments; error bars correspond to s.e.m. NS, not signficant.
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Figure 4. AMD11070 is a specific CXCR4 inhibitor. Absolute migration
of activated T cells towards 10nM of CXCL11 or CXCL12 with and
without 6.6mM AMD11070 for 90min across a 3mm pore filter. Data
represent mean values of three independent experiments; error bars
correspond to s.e.m. NS, not significant; PBS, phosphate-buffered
saline.
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Figure 2. Melanoma cells migrate towards CXCL12. (A) Fluorescence-
activated cell sorting analysis of the expression of the chemokine
receptor CXCR4 on two melanoma cell lines: CHL-1 and A375. Black
histograms correspond to cells incubated with the CXCR4 receptor-
specific antibody, and white histograms correspond to cells incubated
with the isotype-matched control antibody. (B) Dose–response
migration of melanoma cells line CHL-1 (white bars) and A375 (black
bars) migrated for 16 h across an 8-mm pore size filter towards the
indicated concentration of CXCL12. Data represent mean values of
three independent experiments; error bars correspond to s.e.m. HPF,
high-power field.
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AMD11070 is an orally bioavailable antagonist of CXCR4, able to
achieve plasma concentrations of 6.6mM (when administered at an
oral dose of 400mgkg 1 in fasted healthy volunteers; Stone et al,
2007), and which selectively inhibits the binding of CXCR4 to
CXCL12 (Mosi et al, 2012). No apparent acute toxicity was observed
in oral bioavailability studies using AMD11070 and other CXCR4
antagonists have not resulted in any mechanism-based toxicity (Dale
et al, 2012), suggesting that CXCR4 is a safe therapeutic target. We
therefore examined the ability of AMD11070 to disrupt the
chemokine-driven migration of melanoma cells.
Oncogenic mutations in oncogenic B-RAF are common in
melanoma, specifically a V600E mutation. Feedback loops in
melanoma signalling networks demonstrate that B-RAF-V600E is
able to regulate both the MAPK and AKT pathways (Chen et al, 2012).
As well as effects on growth and survival, B-RAF may also
influence tumour migration. Previous work has demonstrated that
B-RAF mediates the migratory response to the chemokine CXCL8
in neutrophils (Knall et al, 1995). CHL-1 cells, which express WT
B-RAF were transfected with vectors encoding WT or V600E
B-RAF and migrated towards CXCL12 in the presence or absence
of AMD11070. Consistent with previous studies, transfection of
V600E into WT B-RAF melanoma cells increased ERK activation
(Chen et al, 2012). Importantly for melanoma, where up to 60% of
patients harbour activating B-RAF mutations, V600E expression
did not affect susceptibility to AMD11070. Densitometric analysis
confirmed that the vast majority of B-RAF present in these cells
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Figure 5. (A) Effect of CXCR4 inhibition on melanoma migration.
Chemotaxis assay using CHL-1 (black bars) and A375 (white bars)
migrated for 16 h towards 10nM CXCL12 across an 8-mm pore size filter
in the presence of 6.6mM AMD11070. (B) Live cell scratch assays were
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of void (pixel number) of control A375-RFP cells or following treatment
over 24 h (time 0, 6, 7, 8, 12, 16, 20 and 24h with 2 mM AMD3100 or
6.6mM AMD11070. Data represent mean values of three independent
experiments; error bars correspond to s.e.m. HPF, high-power field.
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Figure 6. (A) Effect of B-RAF-V600E on melanoma migration. Western
blotting for B-RAF in melanoma cell lines with densitometric
quantification. (B) Western blotting as indicated in CHL-1 transiently
transfected with WT or V600E B-RAF. (C) CHL-1 cells transfected with
either WT (black bars) or mutant (V600E) (grey bars) B-RAF migrated for
16 h towards 10nM CXCL12 across an 8-mm pore size filter in the
presence of 6.6mM AMD11070. HPF, high-power field.
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was due to the transfected plasmid, and intriguingly, transfection
with WT or V600E B-RAF increased the maximum response to
CXCL12, suggesting that the total amount of B-RAF is able to
modulate chemotaxis. Furthermore, V600E-transfected CHL-1
cells had a significantly higher background migration than
mock-transfected or those transfected with WT B-RAF. This
suggests a possible additional oncogenic role for V600E, in that
these cells were more motile even in the absence of exogenous
ligand. However, a confounding caveat is that V600E was
expressed at a slightly higher level than WT, a typical observation
in this system (Armstrong et al, 2011).
We describe a clear mechanism for the site-specific metastasis of
melanoma; liver-resident myofibroblasts excrete CXCL12, which is
able to promote the migration of CXCR4-expressing tumour cells
from the blood into the liver. Data suggest that AMD11070 will
possess antimetastatic therapeutic efficacy in patients with tumours
harbouring WT or mutant B-RAF in excess of that achievable with
AMD3100 by preventing migration towards condition media from
activated primary myofibroblasts. Although there is a potential for
other cytokines produced by myofibroblasts to promote tumour
metastasis, this experiment indicates that the production of
CXCL12 plays a major role in melanoma metastasis, suggesting
that antagonism of CXCR4 by AMD11070 will prevent the
migration of melanoma cells to the liver. Interestingly, over-
expression of mutant B-RAF increased melanoma cell migration
but did not abrogate sensitivity to the AMD3100 inhibitor.
Taken together, these data suggest that AMD11070 may provide
a promising new therapy for preventing melanoma metastasis to
the liver. However, additional preclinical studies are required to
solidify our findings and to translate them into a clinical setting.
Such efforts would require the validation of a suitable model of
human metastatic melanoma, lack of which represents a significant
barrier to translational research in metastatic disease. Nevertheless,
the benefits of AMD11070 may not be limited only to melanoma
patients as CXCR4 is highly expressed by many other cancers,
including breast cancer, lung cancer, neuroblastoma, colorectal
cancer and ovarian cancer.
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